D5A-43716-13894
3 vaccinations
1 coded response
2 check-ins
1 free-text entry
0 call cases
- Sex
- Male
- Age at first dose
- 0-4
- ZIP prefix
- 282 / NC
- Registered
- 2022-07-02
- Relationship
- Child or adolescent in my care
- Guardian
- 5ND-27831-67805
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-11-04
Dose 1 — Moderna
-
2021-12-02
Dose 2 — Moderna
-
2022-07-02
Registered in v-safe
-
2022-08-12
Dose 3 — Pfizer-BioNTech
-
2022-11-11
Survey response — 3 months, dose 3, dependentMedDRA: Cough, Hypersensitivity, Pre-existing disease — Feeling: Fair · Be unable to work or attend schoolFree text: Resurgence of either allergies or RSV or something causing coughing and nebulizer treatments.MedDRA releases: 2024-11 · check-in free text available
- 2023-02-12
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-11-04 | Moderna | No |
| 2 | 2021-12-02 | Moderna | No |
| 3 | 2022-08-12 | Pfizer-BioNTech | No |
Free text
Release 12 — 3 months, dose 3, dependent
Symptoms: Resurgence of either allergies or RSV or something causing coughing and nebulizer treatments.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Hypersensitivity | · | · | ✓ |
| SD | Pre-existing disease | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release